Latest News

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.
Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

March 17th 2025

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies

March 17th 2025

Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.
Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies

March 7th 2025

BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!
BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

March 3rd 2025

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.
Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

February 14th 2025

More News